Elypta is a Swedish cancer diagnostics company focused on reducing cancer mortality by enabling earlier detection and closer monitoring. The metabolism-based liquid biopsy platform measures a novel panel of glycosaminoglycan biomarkers (GAGome) and algorithms trained to detect cancer-specific signatures. Elypta is advancing a comprehensive study program across different cancers, with the leading indications being early detection of recurrence in renal cell carcinoma and multi-cancer screening.

Karl Bergman, CEO

Karl has served as CEO at Elypta since its inception. Karl previously led digitalization efforts as Chief Digital Officer at Praktikertjänst, Sweden’s largest private healthcare provider. Before that, he was a Principal in Arthur D. Little’s healthcare & life science practice where he spent eight years assisting clients with strategic challenges across pharma, diagnostics, and MedTech. Karl holds M.Sc. degrees in Bioengineering as well as in Innovation & Entrepreneurship from Chalmers University of Technology and an MBA from the University of Cambridge.

Francesco Gatto, Founder & Chief Scientific Officer

Francesco founded Elypta with his Ph.D. advisor Jens Nielsen in 2017, oversees the technical plan, and leads all scientific projects at Elypta, acting as deputy CEO. A recipient of the Karin Markides Prize, the National SKAPA Innovation Prize in Memory of Alfred Nobel, and an MIT Technology Review 35 Under 35, his research resulted in 4 patent families paving the way for the foundation of Elypta. Francesco holds a B.Sc. and M.Sc. in Chemical Engineering from the University of Padova, Italy, and a Ph.D. in Systems Biology at Chalmers University of Technology, Sweden. In 2016, he was Visiting Scholar at the University of California, San Diego in Bernhard Palsson lab, and is currently the Visiting Researcher at Karolinska Institute, Sweden in Jonas Bergh Lab.